TrialOCS-01 in Treating Inflammation and Pain in Post-cataract Patients
Trial details
- Registry ID
- NCT04130802
- Phase
- Phase 2
OCS
Oculis
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
9Trials in this database
8Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceOCS-05 in Patients With Optic Neuritis
Trial details
- Registry ID
- NCT04762017
- Phase
- Phase 2
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
Trial details
- Registry ID
- NCT05066997
- Phase
- Phase 2, Phase 3
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Trial details
- Registry ID
- NCT05147233
- Phase
- Phase 3
Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease
Trial details
- Registry ID
- NCT05896670
- Phase
- Phase 2
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Trial details
- Registry ID
- NCT06128369
- Phase
- Phase 3
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
Trial details
- Registry ID
- NCT06172257
- Phase
- Phase 3
A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
Trial details
- Registry ID
- NCT07548632
- Phase
- Phase 2, Phase 3
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
Trial details
- Registry ID
- NCT07623668
- Phase
- Phase 3
Latest recorded trial changes
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
NCT06128369 · Oculis
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Absence of Anterior Chamber Cells at Visit 6. Measure: Absence of Pain at Visit 4.
+ After
Measure: Absence of Anterior Chamber Cells at Visit 6. Measure: Absence of Ocular Pain at Visit 4.
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
NCT05066997 · Oculis
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Apr 2026
+ After
10 Apr 2026
Recruitment status changed
− Before
Active not recruiting
+ After
Completed
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
NCT06172257 · Oculis
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Apr 2026
+ After
2 Apr 2026
Recruitment status changed
− Before
Active not recruiting
+ After
Completed
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
NCT06128369 · Oculis
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Absence of Anterior Chamber Cells at Visit 6.
Measure: Absence of Ocular Pain at Visit 4.
+ After
Measure: Absence of Anterior Chamber Cells at Visit 6. Measure: Absence of Pain at Visit 4.